| 000 | 01851 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250517153018.0 | ||
| 264 | 0 | _c20180507 | |
| 008 | 201805s 0 0 eng d | ||
| 022 | _a1941-837X | ||
| 024 | 7 |
_a10.1080/13696998.2017.1328423 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aCristino, Joaquim | |
| 245 | 0 | 0 |
_aCost-effectiveness of denosumab versus zoledronic acid for preventing skeletal-related events in the Czech Republic. _h[electronic resource] |
| 260 |
_bJournal of medical economics _cAug 2017 |
||
| 300 |
_a799-812 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial | ||
| 650 | 0 | 4 |
_aBone Density Conservation Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aBone Diseases _xetiology |
| 650 | 0 | 4 |
_aBreast Neoplasms _xcomplications |
| 650 | 0 | 4 | _aCost-Benefit Analysis |
| 650 | 0 | 4 | _aCzech Republic |
| 650 | 0 | 4 |
_aDenosumab _xadministration & dosage |
| 650 | 0 | 4 |
_aDiphosphonates _xadministration & dosage |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImidazoles _xadministration & dosage |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMarkov Chains |
| 650 | 0 | 4 | _aModels, Econometric |
| 650 | 0 | 4 |
_aNeoplasms _xcomplications |
| 650 | 0 | 4 |
_aProstatic Neoplasms _xcomplications |
| 650 | 0 | 4 | _aQuality of Life |
| 650 | 0 | 4 | _aQuality-Adjusted Life Years |
| 650 | 0 | 4 | _aZoledronic Acid |
| 700 | 1 | _aFinek, Jíndřich | |
| 700 | 1 | _aJandova, Petra | |
| 700 | 1 | _aKolek, Martin | |
| 700 | 1 | _aPásztor, Bálint | |
| 700 | 1 | _aGiannopoulou, Christina | |
| 700 | 1 | _aQian, Yi | |
| 700 | 1 | _aBrezina, Tomas | |
| 700 | 1 | _aLothgren, Mickael | |
| 773 | 0 |
_tJournal of medical economics _gvol. 20 _gno. 8 _gp. 799-812 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1080/13696998.2017.1328423 _zAvailable from publisher's website |
| 999 |
_c27155237 _d27155237 |
||